A Pilot Study of TRV130 for the Treatment of Fracture Pain

NCT02520297 ↗

Phase 2 Terminated 1 enrolled Trevena Inc. Kestrel Biologic · collab

NaSingle-groupOpen-labelTreatment

Summary

The primary objective is to evaluate the analgesic efficacy of TRV130 for moderate to severe acute pain in patients presenting to the emergency department (ED) with a suspected/known, unilateral, closed long bone fracture.

Timeline

Start: 2015-10-20
Primary completion: 2015-10-23
Completion: 2015-10-23

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Oliceridine	Other / unclassified	—	—

Indications

No indication recorded.